Cited by 598Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

National Trends in Ambulatory Oral Anticoagulant Use

Open access

Barnes, Geoffrey D., Lucas, Eleanor, Alexander, G. Caleb, Goldberger, Zachary D.·2015·The American Journal of Medicine

DOI 10.1016/j.amjmed.2015.05.044PMC PMC4658248

Open this paper in CoChat — free account Open PDF

Abstract

Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing, and promotion, may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased under-treatment of atrial fibrillation.Methods We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014.Results Overall, visits with anticoagulation use increased from 2.05 (95% confidence interval [CI], 1.82-2.27) to 2.83 (95% CI, 2.49-3.17) million (M) quarterly visits (P < .001). Of these, DOAC use has grown to 4.21M (95% CI, 3.63M-4.79M; 38.2% of total) treatment visits in 2014 since their introduction in 2010. Use of all oral anticoagulants in treatment visits for atrial fibrillation has increased from 0.88M (95% CI, 0.74M-1.02M) to 1.72M (95% CI, 1.47M-1.97M; P < .001), with similar DOAC and warfarin use in 2014. Atrial fibrillation visits with anticoagulant use increased from 51.9% (95% CI, 50.4%-53.8%) to 66.9% (95% CI, 65.0%-69.3%) between 2009 and 2014 (P < .001). In 2014, rivaroxaban was the most commonly prescribed DOAC for atrial fibrillation (47.9% of office visits), followed by apixaban (26.5%) and dabigatran (25.5%).Conclusions Direct oral anticoagulants have been adopted rapidly, matching the use of warfarin, and are associated with increased use of oral anticoagulation for patients with atrial fibrillation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2015.05.044

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Ogilvie, I. M., Newton, N., Welner, S. A., Cowell, W., & Lip, G. Y. H. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.025 · Cited by 929

Show all 41 references

Sorted by citations

Items 101–200 of 597

Trends in oral anticoagulant use in Qatar: a 5-year experience
Elewa, H. F., Al-Haddad, A. A. K., Al-Rawi, S., Nounou, A., Mahmoud, H. A. A., & Singh, R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1474-4 · Cited by 31
H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review
Almufleh, A. S., Ramirez, F. D., So, D. Y. F., May, M. R. L., Chong, A., Torabi, N., & Hibbert, B. M. (2018) · Cardiology · doi:10.1159/000489165 · Cited by 31
Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non–Vitamin K Oral Anticoagulants
Loikas, D., Forslund, T., Wettermark, B., Schenck-Gustafsson, K. G., Hjemdahl, P., & von Euler, M. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.002 · Cited by 30
A Contemporary Assessment of Mechanical Complication Rates and Trainee Perceptions of Central Venous Catheter Insertion
Heidemann, L. A., Nathani, N., Sagana, R. L., Chopra, V., & Heung, M. (2017) · Journal of Hospital Medicine · doi:10.12788/jhm.2784 · Cited by 30
Role of the anticoagulant monitoring service in 2018: beyond warfarin
Clark, N. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.348 · Cited by 31
Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012–2017
Yu, Z., Yu, L., & Shan, C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-5072-3 · Cited by 33
Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
Toorop, M. M. A., van Rein, N., Nierman, M. C., Vermaas, H. W., Huisman, M. V., van der Meer, F. J. M., Cannegieter, S. C., & Lijfering, W. M. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12316 · Cited by 30
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA)
Rogers, K. C., & Finks, S. W. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.06.028 · Cited by 29
The Role Of NOACs in Atrial Fibrillation Management: A Qualitative Study.
Kirley, K., GouthamRao, Bauer, V., & Masi, C. M. (2016) · PubMed Central · doi:10.4022/jafib.1416 · Cited by 29
The relationship between DOAC levels and clinical outcomes: The measures tell the tale
Toorop, M. M. A., Lijfering, W. M., & Scheres, L. J. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15104 · Cited by 29
Acute Compartment Syndrome: Do guidelines for diagnosis and management make a difference?
Bodansky, D., Doorgakant, A., Alsousou, J., Iqbal, H., Fischer, B., Scicluna, G., Bowers, M., & Narayan, B. (2018) · Injury · doi:10.1016/j.injury.2018.04.020 · Cited by 28
Safety and efficacy of direct‐acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single‐center cohort study
Bixby, A. L., Shaikh, S. A., Naik, A. S., Cotiguala, L., McMurry, K. A., Samaniego, M., Marshall, V. D., & Park, J. M. (2020) · Transplant International · doi:10.1111/tri.13599 · Cited by 29
Anticoagulation therapy in patients with traumatic brain injury: An Eastern Association for the Surgery of Trauma multicenter prospective study
Matsushima, K., Leichtle, S. W., Wild, J. L., Young, K., Chang, G., Δημητριάδης, Δ., Lomangino, C., Massetti, J. M., Glass, N. E., Livingston, D. H., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.07.040 · Cited by 28
High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy
Manzoor, B. S., Walton, S. M., Sharp, L. K., Galanter, W., Lee, T. A., & Nutescu, E. A. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1565-2 · Cited by 28
Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey
Papastergiou, J., Kheir, N. M., Malá‐Ládová, K., Rydant, S., Rango, F. D., Antoniou, S., Viola, R., Murillo, M. D., Steurbaut, S., & da Costa, F. A. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0551-2 · Cited by 29
How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues
Tripodi, A., Braham, S., Scimeca, B., Moia, M., & Peyvandi, F. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4287 · Cited by 27
Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
Jordan, S. E., Logan, P., Panes, G., Vaismoradi, M., & Hughes, D. (2018) · Pharmacy · doi:10.3390/pharmacy6030102 · Cited by 29
Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants.
Momin, J. H., Candidate, P., & Hughes, G. J. (2019) · PubMed Central · Cited by 27
Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
Wu, J. H., Zhang, Y., Liao, X., & Lei, Y. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00350 · Cited by 26
Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves
Duan, L., Doctor, J. N., Adams, J., Romley, J. A., Nguyen, L.-A., An, J., & Lee, M. S. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.01.016 · Cited by 29
Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans
Steiner, H. E., Giles, J. B., Patterson, H. K., Feng, J., Rouby, N. M. E., Claudio, K., Marcatto, L. R., Tavares, L. C., Gálvez, J. M., Calderón‐Ospina, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749786 · Cited by 29
Investigation of Direct-Acting Oral Anticoagulants and the Incidence of Venous Thromboembolism in Patients Weighing ≥120 kg Compared to Patients Weighing <120 kg
Aloi, K. G., Fierro, J. J., Stein, B. J., Lynch, S. M., & Shapiro, R. J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854578 · Cited by 28
Prevalence and Knowledge of Potential Interactions Between Over‐the‐Counter Products and Apixaban
Tarn, D. M., Barrientos, M., Wang, A. Y., Ramaprasad, A., Fang, M. C., & Schwartz, J. B. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16193 · Cited by 27
Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant
Hale, Z. D., Kong, X., Haymart, B., Gu, X., Kline-Rogers, E. M., ALMANY, S. L., Kozłowski, J., Krol, G. D., Kaatz, S. S., Froehlich, J. B., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1452-2 · Cited by 26
Self-citation
Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice
Valencia, D., Spoutz, P. M., Stoppi, J., Kibert, J. L., Allen, A. L., Parra, D., & Hough, A. R. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019835843 · Cited by 26
Is anticoagulation reversal necessary prior to surgical treatment of geriatric hip fractures?
Meinig, R., Jarvis, S., Orlando, A., Nwafo, N., Banerjee, R. K., McNair, P. W., Woods, B., Harrison, P., Nentwig, M., Kelly, M. C., et al. (2019) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2019.10.004 · Cited by 26
Pull back the curtain: External data validation is an essential element of quality improvement benchmark reporting
Jakubus, J. L., Pasquo, S. L. D., Mikhail, J. N., Cain‐Nielsen, A. H., Jenkins, P. C., & Hemmila, M. R. (2020) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002579 · Cited by 27
Massive Gastrointestinal Hemorrhage
D’Amore, K., & Swaminathan, A. (2020) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2020.06.008 · Cited by 26
Time to surgery and complications in hip fracture patients on novel oral anticoagulants: a systematic review
Cheung, Z. B., Xiao, R. C., & Forsh, D. A. (2021) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-020-03701-2 · Cited by 26
Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries
Norby, F. L., Lutsey, P. L., Shippee, N. D., Chen, L. Y., Henning‐Smith, C., Alonso, Á., Walker, R. F., & Folsom, A. R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00502-9 · Cited by 26
Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing
Chiasakul, T., Crowther, M. A., & Cuker, A. C. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100107 · Cited by 26
Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
Kodani, E., Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., & Origasa, H. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.11.020 · Cited by 26
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate
Bavalia, R., Abdoellakhan, R. A., Brinkman, H. J. M., Brekelmans, M. P. A., Hamulyák, E. N., Zuurveld, M. G., Hutten, B. A., Westerweel, P. E., Olie, R. H., Cate, H. T., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12336 · Cited by 26
Percutaneous Left Atrial Appendage Closure Is a Reasonable Option for Patients With Atrial Fibrillation at High Risk for Cerebrovascular Events
Teíger, E., Thambo, J., Defaye, P., Hermida, J., Abbey, S., Klug, D., Juliard, J., Pasquié, J., Rioufol, G., Lepillier, A., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005841 · Cited by 26
FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals
Herink, M. C., Irwin, A. N., & Zumach, G. M. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2167 · Cited by 26
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial
Nicolau, A. M., Corbalan, R. L., Nicolau, J. C., Ruff, C. T., Zierhut, W., Kerschnitzki, M., Duris, T., Juul‐Möller, S., Voitk, J., Trevisan, M., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz061 · Cited by 25
Racial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 24
Changes in the incidence of out-of-hospital cardiac arrest: Differences between cardiac and non-cardiac aetiologies
Alqahtani, S., Nehme, Z., Williams, B. A., Bernard, S. A., & Smith, K. L. (2020) · Resuscitation · doi:10.1016/j.resuscitation.2020.07.016 · Cited by 25
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention
Secemsky, E. A., Butala, N. M., Kartoun, U., Mahmood, S., Wasfy, J. H., Kennedy, K. F., Shaw, S. Y., & Yeh, R. W. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004310 · Cited by 24
Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital
Miele, C., Taylor, M., & Shah, A. (2017) · Hospital Pharmacy · doi:10.1310/hpj5203-207 · Cited by 24
Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics
Mohammad, I., Korkis, B., & Garwood, C. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1991 · Cited by 24
Delayed Surgery Does Not Reduce Transfusion Rates in Low-Energy Hip Fractures on Direct Oral Anticoagulants
Levack, A. E., Moore, H. G., Stephan, S., Jo, S., Schroeder, I., Garlich, J. M., Hadad, A., Little, M. T. M., Miller, A. N., Lyman, S., et al. (2021) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000002251 · Cited by 24
Review of perioperative outcomes and management of hip fracture patients on direct oral anticoagulants
Wall, P. V., Mitchell, B. C., Ta, C. N., & Kent, W. T. (2023) · EFORT Open Reviews · doi:10.1530/eor-22-0060 · Cited by 24
Patterns of long‐term use of non‐vitamin K antagonist oral anticoagulants for non‐valvular atrial fibrillation: Quebec observational study
Douros, A., Renoux, C., Coulombe, J., & Suissa, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4333 · Cited by 24
Patients Prescribed Direct-Acting Oral Anticoagulants Have Low Risk of Postpolypectomy Complications
Yu, J. X., Oliver, M. S., Lin, J. L., Chang, M. S., Limketkai, B. N., Soetikno, R. M., Bhattacharya, J., & Kaltenbach, T. R. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.051 · Cited by 24
Assessment of direct oral anticoagulant assay use in clinical practice
Gu, T. M., Garcia, D. A., & Sabath, D. E. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1793-0 · Cited by 24
The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis
Bang, C. S., Joo, M. K., Kim, B., Kim, J. S., Park, C. H., Ahn, J. Y., Lee, B. E., Lee, B. E., Yang, H., Cho, Y. K., et al. (2019) · Gut and Liver · doi:10.5009/gnl19009 · Cited by 25
Association of mortality among trauma patients taking preinjury direct oral anticoagulants versus vitamin K antagonists
LaDuke, Z. J., Hecht, J. P., Cain‐Nielsen, A. H., Hemmila, M. R., & Wahl, W. L. (2019) · Surgery · doi:10.1016/j.surg.2019.04.039 · Cited by 23
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis
Milioglou, I., Farmakis, I. T., Neudecker, M., Hussain, Z. G., Guha, A., Giannakoulas, G. A., Kotoula, V., & Papaioannou, M. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02480-w · Cited by 22
Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2714 · Cited by 27
Head computed tomography findings in geriatric emergency department patients with delirium, altered mental status, and confusion: A systematic review
Liu, S. W., Lee, S., Hayes, J. M., Khoujah, D., Lo, A. X., Doering, M. M., & de Wit, K. (2022) · Academic Emergency Medicine · doi:10.1111/acem.14622 · Cited by 22
Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019
Yan, V. K. C., Li, H., Wei, L., Knapp, M. R. J., Wong, I. C. K., & Chan, E. W. (2023) · Drugs · doi:10.1007/s40265-023-01837-0 · Cited by 22
Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
Chen, Q., Toorop, M. M. A., Tops, L. F., Lijfering, W. M., & Cannegieter, S. C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.9973 · Cited by 21
Direct oral anticoagulants: A retrospective study of bleeding, behavior, and documentation
Miller, S., & Miller, C. S. (2018) · Oral Diseases · doi:10.1111/odi.12698 · Cited by 22
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 22
Treatment Failures of Direct Oral Anticoagulants
Kajy, M., Mathew, A., & Ramappa, P. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001083 · Cited by 24
Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study
Fahmi, A. M., Mohamed, A., Elewa, H. F., & Saad, M. O. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619872554 · Cited by 21
Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit
Garwood, C. L., Korkis, B., Grande, D., Hanni, C. M., Morin, A., & Moser, L. R. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1937 · Cited by 21
Treatment in the dental practice of the patient receiving anticoagulation therapy
Kaplovitch, E., & Dounaevskaia, V. (2019) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2019.02.011 · Cited by 21
The risks and characteristics of the delayed bleeding after endoscopic submucosal dissection for early gastric carcinoma in cases with anticoagulants
Saito, H., Igarashi, K., Hirasawa, D., Okuzono, T., Suzuki, K., Abe, Y., Nawata, Y., Tanaka, Y., Tanaka, I., Unno, S., et al. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1817542 · Cited by 21
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial
Turakhia, M. P., H, V. S. M. P., Smith, S. N., Ding, V. Y., Ho, P. M., Kowey, P. R., Piccini, J. P., Foody, J. M., Birmingham, M. C., Ianus, J., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.02.023 · Cited by 21
Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients
Tavares, L. C., Marcatto, L. R., Soares, R. A. G., Krieger, J. E., Pereira, A. C., & Santos, P. C. J. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00542 · Cited by 21
Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis
Fava, J. P., Starr, K. M., Ratz, D., & Clemente, J. L. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618774498 · Cited by 22
The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population
Bader, L., Mahfouz, A., Kasem, M., Mohammed, S., Alsaadi, S., Abdelsamad, O., Elenany, R., Soaly, E., Elzouki, A.-N. Y., Rizk, N. M., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0116-y · Cited by 21
Pharmacogenetics of Warfarin in a Diverse Patient Population
Mak, M., Lam, C., Pineda, S. J., Lou, M., Xu, L. Y., Meeks, C., Lin, C. H., Stone, R., Rodgers, K., & Mitani, G. M. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419843530 · Cited by 21
Quality of Warfarin Therapy and Quality of Life are Improved by Self-Management for Two Years
Sølvik, U. Ø., Løkkebø, E. S., Kristoffersen, A. H., Brodin, E. E., Averina, M., & Sandberg, S. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693703 · Cited by 21
Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
Agrawal, S., Heiss, M. S., Fenter, R. B., Abramova, T. V., Perera, M. A., Pacheco, J. A., Smith, M. E., Rasmussen‐Torvik, L. J., & George, A. L. (2020) · Clinical and Translational Science · doi:10.1111/cts.12781 · Cited by 21
Anticoagulation Reversal
Simon, E., Streitz, M. J., Sessions, D. J., & Kaide, C. G. (2018) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2018.04.014 · Cited by 21
De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxaban en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular
Barrios, V., & Escobar, C. (2016) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2016.01.016 · Cited by 20
Nationwide Implementation of a Population Management Dashboard for Monitoring Direct Oral Anticoagulants: Insights From the Veterans Affairs Health System
Dorsch, M. P., Chen, C. S., Allen, A. L., Sales, A. E., Seagull, F. J., Spoutz, P. M., Sussman, J. B., & Barnes, G. D. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009256 · Cited by 21
Self-citation
Assessing patient preferences for switching from warfarin to direct oral anticoagulants
Wright, J. N., Vazquez, S. R., Kim, K., Jones, A. E., & Witt, D. M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01915-9 · Cited by 20
Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry)
Wong, J. M., Maddox, T. M., Kennedy, K. F., & Shaw, R. E. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.02.028 · Cited by 20
The impact of pre-injury direct oral anticoagulants compared to warfarin in geriatric G-60 trauma patients
Barletta, J. F., Hall, S. A., Sucher, J. F., Dzandu, J. K., Haley, M. M., & Mangram, A. J. (2017) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-017-0772-z · Cited by 19
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study
Pottegård, A., Grove, E. L., & Hellfritzsch, M. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4350 · Cited by 19
Perioperative Management of Chronic Antithrombotic Agents in Elective Hip and Knee Arthroplasty
Santana, D. C., Hadad, M. J., Emara, A. K., Klika, A. K., Barsoum, W. K., Molloy, R. M., Krebs, V. E., Bloomfield, M. R., & Piuzzi, N. S. (2021) · Medicina · doi:10.3390/medicina57020188 · Cited by 19
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
Meihandoest, T., Studt, J., Méndez, A., Alberio, L., Fontana, P., Wuillemin, W. A., Schmidt, A., Graf, L., Gerber, B., Amstutz, U., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.817826 · Cited by 18
The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation
Sychev, D. A., Ostroumova, O. D., Cherniaeva, M. S., Shakhgildian, N., Mirzaev, K. B., Abdullaev, S. P., Денисенко, Н. П., Sozaeva, Z. A., Kachanova, A. A., Вартановна, Г. С., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00536-3 · Cited by 18
Improving inpatient warfarin therapy safety using a pharmacist-managed protocol
Daniels, P. R., Manning, D. M., Moriarty, J. P., Bingener-Casey, J., Ou, N. N., O’Meara, J. G., Roellinger, D. L., & Naessens, J. M. (2018) · BMJ Open Quality · doi:10.1136/bmjoq-2017-000290 · Cited by 18
Dabigatran-induced anticoagulant-related nephropathy with undiagnosed IgA nephropathy in a patient with normal baseline renal function
Ikeda, M., Tanaka, M., Shimoda, S., Saita, H., Nishikawa, S., Shimada, H., Taniguchi, K., Hagihara, K., Iwanari, S., & Takeoka, H. (2019) · CEN Case Reports · doi:10.1007/s13730-019-00410-7 · Cited by 18
Clinical Model for Predicting Warfarin Sensitivity
Ma, Z., Cheng, G., Wang, P., Khalighi, B., & Khalighi, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-49329-0 · Cited by 18
Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study
Maji, D., Opneja, A., Suster, M. A., Bane, K. L., Wilson, B. M., Mohseni, P., & Stavrou, E. X. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1715589 · Cited by 18
Real-World Experience of Holmium Laser Enucleation of the Prostate with Patients on Anticoagulation Therapy
Agarwal, D., Large, T., Stoughton, C. L., Heiman, J. M., Nottingham, C. U., Rivera, M., & Krambeck, A. E. (2020) · Journal of Endourology · doi:10.1089/end.2020.0886 · Cited by 18
Point-of-care testing in the acute management of traumatic brain injury: Identifying the coagulopathic patient
Andaluz, N. O., Gozal, Y., Carroll, C. P., Krueger, B., & Khoury, J. C. (2017) · Surgical Neurology International · doi:10.4103/sni.sni_265_16 · Cited by 18
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
Meihandoest, T., Studt, J., Méndez, A., Alberio, L., Fontana, P., Wuillemin, W. A., Schmidt, A., Graf, L., Gerber, B., Maeder, G. M., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.717939 · Cited by 18
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
Grymonprez, M., de Backer, T. L., Capiau, A., Vauterin, D., Mehuys, E., Boussery, K., Steurbaut, S., & Lahousse, L. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15582 · Cited by 17
Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going
Marco, F. D., Valli, G., Ancona, C., & Ruggieri, M. P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad004 · Cited by 17
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent
Powell, J., Taylor, J., & Garland, S. G. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019835209 · Cited by 17
Safety of direct‐acting oral anticoagulants relative to warfarin in a matched cohort of liver transplant recipients
Santeusanio, A. D., Weinberg, A. D., Florman, S. S., & Schiano, T. D. (2019) · Clinical Transplantation · doi:10.1111/ctr.13756 · Cited by 17
Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
Konicki, R., Weiner, D., Patterson, J. H., González, D., Kashuba, A. D. M., Cao, Y., Gehi, A. K., Watkins, P. B., & Powell, J. R. (2020) · Clinical and Translational Science · doi:10.1111/cts.12766 · Cited by 20
Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation
Sanghai, S., Liu, W., Wang, W., Rongali, S., Orkaby, A. R., Saczynski, J. S., Rose, A. J., Kapoor, A., Li, W., Yu, H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06834-1 · Cited by 17
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta‐analysis of 92 studies
Barakakis, P. A., Li, W., Kalaitzoglou, D., Tzelves, L. I., Manolopoulos, A., Giannopoulos, S., Giamouzis, G., Giannakoulas, G. A., Batsidis, A., Palaiodimos, L., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15464 · Cited by 17
Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding
Uyhazi, K. E., Miano, T. A., Pan, W., & VanderBeek, B. L. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.5677 · Cited by 17
Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations
Rouby, N. M. E., Shahin, M. H., Bader, L., Khalifa, S. I., & Elewa, H. F. (2021) · Clinical and Translational Science · doi:10.1111/cts.13176 · Cited by 16
Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin
Cheng, S., Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000876 · Cited by 16
Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum
Burnett, A., Rudd, K. M., & Triller, D. M. (2022) · Thrombosis Update · doi:10.1016/j.tru.2022.100125 · Cited by 16
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System
Buck, J., Kaboli, P. J., Gage, B. F., Cram, P. M., & Vaughan‐Sarrazin, M. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.03.029 · Cited by 16
Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting
Russo‐Alvarez, G., Martinez, K. A., Valente, M., Bena, J., Hu, B., Luxenburg, J., Chaitoff, A. M., Ituarte, C. M., Brateanu, A., & Rothberg, M. B. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017727290 · Cited by 16
Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis
Abdulhadi, B., Mulki, R., Goyal, A., & Rangaswami, J. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221641 · Cited by 16
Intracerebral hemorrhage in the mouse altered sleep-wake patterns and activated microglia
Giordano, K. R., Denman, C. R., Dollish, H. K., Fernandez, F., Lifshitz, J., Akhter, M., & Rowe, R. K. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113242 · Cited by 16
Comparison of fibrin sealants in peripheral vascular surgery: A systematic review and network meta-analysis
Danker, W., DeAnglis, A. P., Ferko, N. C., Garcia, D., & Hogan, A. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.12.003 · Cited by 16

Authors: Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D.
Affiliations: University of Michigan (US)
Johns Hopkins University (US)
University of Washington (US)
Corresponding author: Barnes, Geoffrey D.
ORCID: Barnes, Geoffrey D.
Lucas, Eleanor
Alexander, G. Caleb
Goldberger, Zachary D.
Venue: The American Journal of Medicine
Publisher: Elsevier BV
Published: 2015-12
Volume: 128
Issue: 12
Pages: 1300-1305.e2
ISSN: 0002-9343 (ISSN-L)
DOI: 10.1016/j.amjmed.2015.05.044
PMC: PMC4658248
OpenAlex: W826970266
Cited by: 598
References: 41
Citations by year: 2026: 11 · 2025: 25 · 2024: 23 · 2023: 38 · 2022: 72 · 2021: 69 · 2020: 87 · 2019: 97 · 2018: 83 · 2017: 61 · 2016: 29 · 2015: 1
FWCI: 42.18
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The American Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (R01 HL107345, T32 HL007853-16)
Portola Pharmaceuticals
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: direct oral anticoagulants, warfarin, atrial fibrillation, venous thromboembolism, outpatient care, rivaroxaban, apixaban, dabigatran, prescribing patterns, drug adoption
MeSH terms: Rivaroxaban, Dabigatran, Administration, Oral, Adult, Age Factors, Aged, Ambulatory Care, Anticoagulants, Atrial Fibrillation, Female, Humans, Male, Middle Aged, Practice Patterns, Physicians', Pyrazoles, Pyridones, United States, Warfarin, Venous Thromboembolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

National Trends in Ambulatory Oral Anticoagulant Use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks